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Abstract
Matrix metalloproteinases (MMPs) play a crucial role in migration of inflammatory cells into the 
central nervous system (CNS). Levels of MMP-9 are elevated in multiple sclerosis (MS) and 
predict the occurrence of new active lesions on magnetic resonance imaging (MRI). This 
translational study aims to determine whether in vivo treatment with the pregnancy hormone 
estriol affects MMP-9 levels from immune cells in patients with MS and mice with experimental 
autoimmune encephalomyelitis (EAE). Peripheral blood mononuclear cells (PBMCs) collected 
from three female MS patients treated with estriol and splenocytes from EAE mice treated with 
estriol, estrogen receptor (ER) α ligand, ERβ ligand or vehicle were stimulated ex vivo and 
analyzed for levels of MMP-9. Markers of CNS infiltration were assessed using MRI in patients 
and immunohistochemistry in mice. Supernatants from PBMCs obtained during estriol treatment 
in female MS patients showed significantly decreased MMP-9 compared to pre treatment. 
Decreases in MMP-9 coincided with a decrease in enhancing lesion volume on MRI. Estriol 
treatment of mice with EAE reduced MMP-9 in supernatants from autoantigen stimulated 
splenocytes, coinciding with decreased CNS infiltration by T cells and monocytes. Experiments 
with selective ER ligands revealed that this effect was mediated via ERα. In conclusion, estriol 
acting via ERα to reduce MMP-9 from immune cells is one mechanism potentially underlying the 
estriol-mediated reduction in enhancing lesions in MS and inflammatory lesions in EAE.
Keywords
Estriol; Experimental Autoimmune Encephalomyelitis; Leukocyte Transmigration; Multiple 
Sclerosis
Matrix metalloproteinases (MMPs), particularly MMP-9, have been implicated in the 
disruption of the blood-brain barrier (BBB) in MS because the capacity of T cells and 
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monocytes to transmigrate into the CNS has been shown to be dependent upon the activity 
of MMP-9. Levels of MMPs have been found to be upregulated in several inflammatory 
CNS diseases (1) including MS where autopsy studies have shown that MMP-9 is increased 
in macrophages and lymphocytes within perivascular cuffs (2). Furthermore, serum and CSF 
levels of MMP-9 are higher in relapsing remitting multiple sclerosis (RRMS), particularly in 
patients during relapse and in those with enhancing lesions on MRI (3–6). Increased MMP-9 
serum levels have also been found in patients with clinically isolated syndrome and MMP-9 
levels further increased in patients who developed clinically definite MS compared to stable 
levels in patients who did not convert (7).
During pregnancy, relapse rates in MS are decreased by approximately 80% during the last 
trimester (8), a time when the pregnancy hormone estriol reaches its highest levels. Studies 
in experimental autoimmune encephalomyelitis (EAE), the animal model of MS, have 
shown that estriol treatment ameliorates disease (9, 10) and decreases inflammatory lesions 
in the spinal cord (11). Anti-inflammatory effects of estrogens are complex and include 
effects on chemokines, cytokines, dendritic cell function, and T regulatory cell 
subpopulations (12). Estriol has been shown to downregulate TNFα (10), a cytokine known 
to activate MMP-9 (13). Consistent with the anti-inflammatory effects of estriol in EAE, a 
recent pilot study of estriol treatment in female MS patients showed decreased levels of 
TNFα from peripheral blood mononuclear cells (14) and decreases in the number and 
volume of gadolinium-enhancing lesions on MRI (15). Finally, T cells obtained from MS 
patients, which were treated in vitro with pregnancy levels of estriol showed decreased 
MMP-9 levels and lower migratory capacity in vitro (16). What remains unclear is whether 
MMP-9 downregulation occurs in vivo when estriol is administered at a pregnancy dose and 
if this is related to decreases in markers of CNS infiltration during autoimmune 
demyelinating disease. In addition, it is unclear whether this effect is mediated through 
estrogen receptor (ER) α or ERβ.
Materials and Methods
Female RRMS patients
Peripheral blood mononuclear cells (PBMCs) were obtained from three premenopausal 
female patients with clinically definite RRMS who had participated in our pilot trial of oral 
estriol treatment with 8 mg/day for a duration of 6 months (15). The study was approved by 
the UCLA Human Subjects Protection Committee, and informed consent was obtained. The 
dose used has been shown to yield estriol levels in the blood that approximated 6-month 
pregnancy levels in humans (15). PBMCs were isolated and cryopreserved at three time 
points: prior to estriol treatment, at the end of the six month estriol treatment period, and 3 
months after the cessation of treatment.
PBMC cultures, MMP measurement and intracellular MMP-9 staining
PBMCs were cultured at 1 × 105 per well with PHA (5 µg/ml; Sigma-Aldrich, at 37C, 5% 
CO2) and supernatants were harvested after 48h. Culture supernatants were assayed for 
levels of MMP-9, its inhibitor TIMP-1, MMP-2 and its inhibitor TIMP-2 using SearchLight 
multiplex assays. To assess functional proteolytic activity of MMP-9 in the PBMC cell 
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culture supernatants, zymography assays were used. Supernatants were diluted 1/1 in 2× 
zymogram sample dilution buffer (NOVEX, San Diego, CA). Then, 10 ml of diluted sample 
was loaded onto a precast 10% Tris/glycine gel with 0.1% gelatin incorporated as substrate 
(NOVEX). Gels were electrophoresed at 125 V for 90 minutes and then renatured for 30 
min in 1× renaturing buffer (NOVEX) at room temperature. This was followed by 
incubation in 1× developing buffer at 37°C for 18 h. Gels were stained in 0.5% Coomassie 
blue R-250 (Bio-Rad, Hercules, CA) dissolved in 30% methanol/10% acetic acid and 
destained in the same solution without dye. Gels were scanned using an Epson 4870 
scanner, and converted to grayscale in Adobe Photoshop. Band intensities were quantified 
by ImageJ software using the semi-automated Gel Analysis Tool.
For intracellular MMP-9 staining, PBMCs were stimulated with 5µg/ml PHA for 24 hours in 
the presence of monensin (2µM) to allow for intracellular accumulation. Cells were washed 
and stained with conjugated surface antibodies for CD3 (APC), CD14 (APC), CD16 
(PerCp), and CD56 (PE) (Biolegend, San Diego, CA), washed, fixed and permeabilized with 
Cytofix/Cytoperm solution (BD PharMingen, San Diego, CA). Then, cells were stained with 
FITC-labeled Ab specific for MMP-9 or isotype control (R&D Systems, Minneapolis, MN), 
washed and resuspended for FACS analysis on a FACSCalibur instrument (BD Biosciences, 
San Diego, CA) using CellQuest software (BD Biosciences, San Diego, CA).
Brain MRI and lesion quantification
MRI scans obtained in RRMS patients in the estriol trial were analyzed at three time points: 
prior to estriol treatment, in the last month of estriol treatment (month 6) and three months 
after the cessation of treatment. T1-weighted scans with and without gadolinium were 
performed on a 1.5T G.E. scanner. The volume of gadolinium-enhancing lesions was 
determined using a semiautomated threshold based technique (Display; Montreal 
Neurological Institute) as described (15).
Animals
Female C57BL/6 mice, 8 weeks of age, were purchased from Tacomic (Germantown, NY). 
Animals were housed under guidance set by the National Institutes of Health, and 
experiments were conducted in accordance with the University of California, Los Angeles, 
Chancellor’s Animal Research Committee and the Public Service Policy on Humane Care 
and Use of Laboratory Animals.
Active EAE induction
Active EAE induction ensued with subcutaneous injection of an emulsion containing the 
autoantigen, myelin oligodendrocyte glycoprotein (MOG) peptide, amino acids 35–55 
(300µg/mouse) and Mycobacterium tuberculosis (500µg/mouse) in complete Freund’s 
adjuvant. Mice were monitored daily for EAE disease severity using the standard EAE 
grading scale as described (17).
Treatment and reagents
Gonadally intact female mice were treated with 60 day continuous release estriol pellets 
(5mg) or placebo pellets (Innovative Research of America, Sarasota FL) beginning 7 days 
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prior to EAE induction. This dose has previously been shown to yield circulating estriol 
levels that approximated levels of estriol during late natural pregnancy in a mouse (9).
Additional sets of mice were anesthetized with isoflurane, ovariectomized and allowed to 
recuperate for 10 days. Animals were then treated with a selective ERα ligand propyl 
pyrazole triol (PPT) at 10 mg/kg per day, selective ERβ ligand diarylpropionitrile (DPN) at 
8 mg/kg per day, or vehicle beginning 7 days before EAE induction and throughout the 
entire disease duration by daily s.c. injections. These doses of ER ligands have previously 
been shown to yield expected effects on a positive control tissue (uterus) (18). On day 35–40 
after disease induction, animals were sacrificed, spleens removed and animals perfused for 
immunohistochemistry as described (18).
Splenocyte cultures and MMP-9 measurement
Splenocytes were isolated and stimulated in vitro with autoantigen, MOG peptide 35–55, at 
25µg/ml for 48 hours. MMP-9 protein levels were assayed in culture supernatants using 
SearchLight multiplex assays (anti-mouse antibodies). MMP-9 amount in the splenocyte 
culture supernatants was assessed with zymography as described above.
Immunohistochemistry
Spinal cords were isolated from perfused mice and processed as described (18). Free-
floating cross sections (25 µm thick) were cut with a sliding microtome and collected 
serially in PBS. Consecutive sections were examined by immunohistochemistry. The 
following primary antibodies were used for T cells (CD3, 1:500, BD Pharmingen, San 
Diego, CA), and macrophages (Mac3, 1:300, BD Pharmingen, San Diego, CA) and a 
nuclear stain DAPI (2ng/ml; Molecular Probes). Mounted and stained sections were 
examined and photographed using a confocal microscope (Olympus Spin disc confocal 
microscope, Japan). To quantify immunostaining results, sections from thoracic spinal cord 
levels T1–T5 were examined, three from each mouse, with n = 3 mice per treatment group. 
Cell numbers were quantified (at ×40 magnification) by counting the CD3+/DAPI+ and 
Mac3+/DAPI+ positive cells per 100µm2 in the dorsal column of the spinal cord by a 
blinded observer.
Statistical analysis
MMP levels were compared in RRMS patients from pre-treatment to treatment period using 
paired t tests. MMP-9 levels between estriol and vehicle treated mice with EAE were 
compared using independent t tests. MMP-9 levels in groups of mice treated with ERα 
ligand, ERβ ligand or vehicle were compared using one-way ANOVA with Bonferroni-
adjusted post tests. Group differences in EAE scores were tested using repeated measures 
mixed model ANOVA with Bonferroni-adjusted post tests. Group differences in T cell and 
macrophage counts in immunohistochemistry were tested using one way ANOVA with 
Newman-Keuls multiple comparison tests. A value of p<0.05 was considered statistically 
significant. All analyses were computed using GraphPad Prism Software 4.0 for Macintosh.
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Results
MMP-9, but not MMP-2, is decreased by estriol treatment in RRMS
MMP-9 levels and activity were decreased in RRMS patients treated with pregnancy levels 
of estriol. Zymography, an enzymatic activity based assay, showed decreased amounts of 
MMP-9 in supernatants from ex vivo stimulated PBMCs obtained from patients during 
estriol treatment compared to pre and 3 months post after treatment (Figure 1A). In addition, 
during treatment, a significant decrease in MMP-9/TIMP-1 ratio (p=0.04, Figure 1B) was 
observed in supernatants from PBMC cultures. This was driven by significant decreases in 
MMP-9 (p=0.02, Figure 1C), whereas TIMP-1 was not altered (p=0.76, Figure 1D). No 
significant changes were observed in MMP-2/TIMP2 ratio (p=0.51, Figure 1E), MMP-2 
(p=0.81, Figure 1F) or TIMP-2 levels (p=0.60, Figure 1G).
Within the same three RRMS patients, changes in MMP-9 were accompanied by a 
simultaneous decrease in enhancing (Gd+) lesion volume during estriol treatment as 
compared to before treatment (Figure 1H), consistent with our previous publication showing 
that estriol treatment significantly decreases Gd+ lesions (15). Representative scans from 
one subject at baseline and during treatment (Figure 1I) show resolution of an enhancing 
lesion (white arrow). Flow cytometric analysis revealed that T cells were a major source of 
MMP-9 in PBMCs stimulated with PHA (Figure 1 J). This however does not rule out 
MMP-9 production by non-T cells using other stimulation conditions.
Estriol treatment decreases MMP-9 in EAE
Next, we ascertained whether we could replicate the observation from the estriol trial in 
female RRMS patients by administering estriol treatment to female C57BL/6 mice with 
EAE. Both zymography (p=0.04; Figure 2A–B) and protein measurement by SearchLight 
assays (p<0.001, Figure 2C) showed decreased MMP-9 in supernatants obtained from 
autoantigen-stimulated splenocytes of estriol treated EAE mice compared to vehicle treated. 
Clinically, estriol treatment significantly ameliorated disease severity (p<0.0001; Figure 
2D).
Immunohistochemistry revealed that estriol treatment decreased infiltration by T cells 
(p=0.001; Figure 2 E, representative images shown in Figure 2F and 2G) and macrophages 
(p=0.04; Figure 2E, representative images shown in Figure 2H and 2I) in the spinal cord.
Decrease in MMP-9 in EAE is mediated via ERα
Effects of estrogens are mediated primarily by nuclear receptors ERα and ERβ, which have 
distinct tissue distribution and function. Thus, we next sought to determine whether 
downregulation of MMP-9 by estriol treatment of EAE was mediated via ERα or ERβ. To 
eliminate the effects of endogenous estrogens, female mice were ovariectomized in these 
experiments. Active EAE was induced in female C57BL/6 mice treated with optimal doses 
of a selective ER ligand for ERα (PPT), ERβ (DPN), or with vehicle. Zymography revealed 
decreased MMP-9 in autoantigen-stimulated splenocyte supernatants from ERα (p<0.05) but 
not ERβ ligand treated EAE mice (p>0.05) compared to vehicle treated (Figure 3A–C). This 
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was confirmed by significant decreases in MMP-9 protein levels in splenocyte supernatant 
from ERα (p<0.01), but not ERβ ligand (p>0.05) treated EAE mice (Figure 3D).
Clinically, ERα ligand treatment was associated with an early and complete abrogation of 
disease (p< 0.0001, Figure 3E). ERβ ligand-treated mice, as compared with vehicle-treated 
mice, were not significantly different early in disease (up to day 20 after disease induction) 
but then became significantly improved later during EAE (p< 0.001). 
Immunohistochemistry analysis indicated decreased spinal cord infiltration by T cells 
(Figure 3F, representative images shown in Figure 3G and 3H) and macrophages (Figure 3F, 
representative images shown in Figure 3I and 3J) in ERα ligand (p<0.05) treated but not 
ERβ ligand (p>0.05) treated mice compared to vehicle treated EAE mice.
Discussion
In this study, we found that MMP-9 levels were decreased with estriol treatment at 
pregnancy doses in patients with RRMS. This decrease in MMP-9 coincided with a decrease 
in enhancing lesions on MRI. We then showed that MMP-9 levels were also decreased with 
estriol treatment at pregnancy doses in mice with EAE. Finally, we used this model to show 
that the estriol-mediated decrease in MMP-9 coincided with a decrease in T cell and 
macrophage infiltration into the CNS and that this decrease was mediated through ERα.
Estrogens have a wide range of effects on the immune system that could be protective in 
EAE including downregulation of cytokines, chemokines, dendritic cell function, and 
induction of regulatory T cells (12). Since estrogens are endogenous regulators of a great 
number of biological functions, a wide range of effects in the immune system is expected 
and no single mechanism is likely to be solely responsible for the protective effects in 
autoimmune disease. In the context of MS and EAE, MMP-9 may be of importance because 
it plays a key role in transmigration of immune cells into the CNS, which is an early step in 
our current understanding of MS pathogenesis. MMP-9 is selectively expressed on Th1 cells 
compared to Th2 cells and is responsible for a higher migratory capacity of Th1 cells (19). 
Human monocytes have also been found to express high levels of MMP-9, which was linked 
to their migratory capacity in experimental models of the blood brain barrier (20). The 
importance of MMP-9 in autoimmune inflammation is further underscored by a study 
demonstrating that GM6001, a matrix metalloproteinase inhibitor, ameliorated the clinical 
severity of EAE and reduced blood brain barrier disruption (21).
MMP-9 has been shown to be decreased by other immunomodulators such as IFNβ (22, 23) 
and minocycline (24). Both drugs are also highly effective in reducing enhancing lesions on 
MRI by approximately 80% within the first three months of treatment (25, 26). In contrast, 
there is no evidence to date that glatiramer acetate (GA) affects MMPs (27). Interestingly, 
GA does not significantly decrease enhancing lesions on serial MRI until month 6–9 of 
treatment (28). The ability of a drug to decrease MMP-9 thus appears to be linked its ability 
to mediate an early and robust reduction in enhancing lesions. Our previous report 
demonstrating that estriol can decrease enhancing lesions by approximately 80% (15) is 
consistent with our finding herein that estriol treatment reduces MMP-9.
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The synthetic estrogen ethinyl estradiol has been shown to decrease TNFα as well as 
MMP-9 activity both in the peripheral immune system and the CNS in EAE (29), which is in 
line with our observation of decreased MMP-9 during treatment with pregnancy doses of 
estriol. Studies using ERα signaling deficient mouse strains have demonstrated that clinical 
protection from EAE by estradiol (30) and estriol (31) depends on signaling through ERα. 
Correspondingly, anti-inflammatory mechanisms of estrogens have been found to be 
mediated by ERα. We have previously reported that treatment with a selective ERα ligand, 
but not with an ERβ ligand, has immunomodulatory effects on peripheral cytokine 
production and reduces CNS infiltration (18). In addition to these peripheral immune effects, 
Garidou et al. (32) have elegantly shown that ERα-mediated regulation of resident CNS 
cells is important for amelioration of EAE. In another study, estradiol decreased MMP-9 
production by microglia in ERβ KO, but not ERα KO, mice in a model of non-autoimmune 
CNS inflammation (33). Together, these results and our findings suggest that estrogens may 
interfere with CNS infiltration by inhibiting MMP-9 both within the periphery and the CNS 
in an ERα-dependent manner.
Interestingly, while ERα ligand treatment abrogated EAE at the onset and throughout the 
disease course, ERβ ligand treatment had no effect at disease onset but promoted recovery 
during the chronic phase of the disease. The late improvement of disability in ERβ treated 
mice is in accordance with our previously published study (18). There, we showed that 
while ERβ ligand treatment had no effects on splenocyte cytokine production and CNS 
inflammation, it reduced demyelination and preserved axon numbers in white matter, as well 
as decreased neuronal abnormalities in gray matter. This suggests a directly neuroprotective 
mechanism of ERβ agonists independent of anti-inflammatory effects. These findings are in 
line with other recent studies using transgenic mice (34) and selective ERβ agonists (35), 
indicating that the beneficial effects of estrogen on cognitive function are dependent on the 
ERβ pathway. Selective ERβ agonist effects on cognition have been linked to increased 
dendritic branching and upregulation of key synaptic proteins including PSD-95, 
synaptophysin, and AMPA-receptor subunit GluR1 in the hippocampus (36). To date, the 
exact mechanisms how ERβ neuroprotection in EAE occurs however remain unclear and are 
the subject of ongoing studies.
Matrix metalloproteinases, and most importantly MMP-9, play a central role for term labor 
when expression and activation of MMP-9 increases during parturition (37). Elevated levels 
of MMP-9 have been implicated in several preterm perinatal complications including 
spontaneous preterm labor, premature rupture of fetal membranes, and preeclampsia (37). 
Thus, MMP activity is tightly regulated during pregnancy. MS patients as well as 
individuals with other inflammatory autoimmune diseases such as rheumatoid arthritis (RA), 
uveitis, and psoriasis experience clinical improvement during pregnancy, with a temporary 
‘rebound’ exacerbation postpartum (8, 38–43). MMP-9 could represent a common 
mechanism for immune cell homing in all of these disorders regardless of the target tissue of 
the autoimmune attack since levels of MMP-9 have been found to be elevated in RA (44), 
psoriasis (44), and uveitis (45, 46), in particular in patients with active disease. In psoriasis, 
effective therapy with anti-TNFα was associated with decreased levels of MMP-9 in serum 
and skin lesions (47). These findings suggest that MMP-9 downregulation may be a shared 
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mechanism that could underlie the decrease in disease activity of inflammatory autoimmune 
disorders such as MS, RA, uveitis, and psoriasis during pregnancy.
This paper has focused on a potential beneficial effect of downregulation of MMP-9 during 
estriol treatment to decrease immune cell infiltration into the target tissue in autoimmune 
disease, however other effects of MMP-9 that could play a role in MS pathology should also 
be considered. For example, high levels of MMPs in the CNS can contribute to 
demyelination and toxicity to axons (48). On the other hand, there is also emerging evidence 
that MMPs may be important for mediation of tissue repair (1). The regulation of these 
multiple and complex mechanisms during pregnancy and estriol treatment warrants further 
investigation.
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BBB blood brain barrier
CNS central nervous system
DPN diarylpropionitrile
EAE experimental autoimmune encephalomyelitis
ER estrogen receptor
MMP matrix metalloproteinases
MOG myelin oligodendrocyte glycoprotein
MS multiple sclerosis
MRI magnetic resonance imaging
PBMC peripheral blood mononuclear cell
PPT propyl pyrazole triol
RRMS relapsing-remitting MS
TIMP tissue inhibitor of metalloproteinases
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Figure 1. MMP-9 regulation by estriol in multiple sclerosis
Six month of estriol treatment reduced MMP-9 bioactivity in peripheral blood mononuclear 
cell (PBMC) culture supernatants (PHA stimulated) as measured by zymography compared 
to pre-treatment (pre) and 3 month after treatment cessation (post) in three female patients 
with relapsing-remitting MS (A). Estriol significantly decreased MMP-9/TIMP1 ratio (B). 
This effect was driven by decreases in MMP-9 levels (C), while estriol had no effect on 
TIMP1 (D). No significant changes were observed on MMP-2/TIMP2 ratio (E), MMP-2 (F), 
or TIMP2 (G). Decreased volumes of gadolinium-enhancing lesions on MRI occurred 
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during estriol treatment (H). Representative scans from one subject show resolution of an 
enhancing lesion (I, white arrow). Intracellular staining using flow cytometry indicated that 
T cells (upper right quadrant) were a major source of MMP-9 in PHA activated PBMCs (J).
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Figure 2. Estriol regulation of MMP-9 in active experimental autoimmune encephalomyelitis 
(EAE)
Autoantigen-stimulated splenocyte cultured supernatants from estriol treated EAE mice 
showed decreased MMP-9 bioactivity (A, quantification in panel B) as measured by 
zymography. Band intensity measurements were normalized by setting the mean band 
intensity of the vehicle treated group as 100%. Values are expressed as relative intensity (%) 
for all animals. Estriol treated animals also showed significantly reduced MMP-9 protein 
levels (C) compared to vehicle treated (n=5 in each group). This was accompanied by 
abrogation of clinical disease (D). Estriol treatment decreased infiltration into the CNS by T 
cells (E). Representative images are shown in panels F–G (T cells are labeled with anti-CD3 
antibodies, green staining). Similarly, estriol treatment decreased CNS infiltration by 
macrophages (E). Representative images are shown in panels H–I (macrophages are labeled 
with anti-Mac3 Gold antibodies, green staining). The nuclear stain DAPI (pseudocolored 
red) was used to identify all cell nuclei. Images show dorsal column of spinal cord at ×10 
magnification (insets at ×40).
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Figure 3. Estriol-induced MMP-9 downregulation in EAE is mediated through ERα
Decreased bioactivity of MMP-9 in supernatants from splenocyte cultures compared to 
vehicle treated was seen in ERα ligand and estriol treated mice, but not in vehicle or ERβ 
ligand treated mice (A pooled supernatants from 4 animals in each group, B supernatants 
from individual animals, C quantification). Band intensity measurements were normalized 
by setting the mean band intensity of the vehicle treated group as 100%. Values are 
expressed as relative intensity (%) for all animals. Significantly decreased MMP-9 protein 
levels were observed in ERα ligand treated EAE mice (n=5) compared to vehicle treated 
EAE (n=4), while there was no difference between vehicle treated and ERβ ligand (n=3) 
treated mice (D). ERα treatment completely abrogated clinical disease (E). ERα, but not 
ERβ, ligand treatment reduced infiltration into the CNS by T cells (F). Representative 
images are shown in panels G–H (T cells are labeled with anti-CD3 antibodies, green 
staining). Similarly, ERα, but not ERβ, ligand treatment decreased macrophages infiltration 
(F). Representative images are shown in panels I–J (macrophages are labeled with anti-
Mac3 antibodies, green staining). The nuclear stain DAPI (pseudocolored red) was used to 
identify all cell nuclei. Images show dorsal column of spinal cord at ×10 magnification 
(insets at ×40).
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